OncoCyte Corp

NASDAQ:OCXUnited States

OncoCyte Corporation is a molecular diagnostics company. The Company is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

Contact Information

Headquarters

15 CUSHINGIRVINE, CA, United States 92618

Phone

949-409-7600

Fax

510-521-3389

Executives

Independent Chairman of the Board

Andrew Arno

President, Chief Executive Officer, Director

Ronald Andrews

Corporate Development Officer

Mitchell Levine

Chief Operating Officer

Gisela Paulsen

Principal Accounting Officer, Vice President, Controller

Li Yu